You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence
Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis
Free
  1. Shinji Akioka
  1. Correspondence to Dr Shinji Akioka, Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto 6028566, Japan; sakioka{at}koto.kpu-m.ac.jp

https://doi.org/10.1136/annrheumdis-2014-206426

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article by Heijstek et al1 regarding the safety of the bivalent human papillomavirus (HPV) vaccine in patients with juvenile idiopathic arthritis (JIA). Their prospective controlled observational cohort study of 68 patients revealed no differences in adverse events between female JIA patients and healthy girls. The authors concluded that the vaccine is well tolerated in JIA patients. Most reports regarding the safety of the HPV vaccine, including premarket cohort studies2–4 and postlicensing safety monitoring surveys,5 suggest no apparent causal relationship between the vaccine and serious adverse events (SAEs) in young girls. Now the focus has …

    View Full Text

    Linked Articles